Use of trans-activation and CIS-activation to increase the persistence of a transgene in an at least E4-deficient adenovirus
US6660521B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2001 |
| Grant date | Dec 9, 2003 |
| Priority date | — |
| Expiry date | Jan 29, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/60
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides a method of modulating the persistence of expression of a transgene in an at least E4&Dgr; adenoviral vector in a cell. In one embodiment, the method comprises contacting the cell with an at least E4&Dgr; adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In another embodiment, the method comprises contacting the cell simultaneously or sequentially with (i) an at least E4&Dgr; adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In addition, the present invention provides a recombinant at least E4&Dgr; adenoviral vector for use in the method and a composition comprising the vector and a carrier therefor. Also provided by the present invention is a system for modulation of a recombinant at least E4&Dgr; adenoviral vector for use in the method and a composition comprising the system and a carrier therefor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.